Cargando…

Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands

BACKGROUND: Streptococcus pneumoniae causes morbidity and mortality among all ages in The Netherlands. To reduce this burden, infants in The Netherlands receive the 10-valent pneumococcal conjugated vaccine (PCV10), but older persons are not targeted. We assessed the impact and cost-effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thorrington, Dominic, van Rossum, Leo, Knol, Mirjam, de Melker, Hester, Rümke, Hans, Hak, Eelko, van Hoek, Albert Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806887/ https://www.ncbi.nlm.nih.gov/pubmed/29425249 http://dx.doi.org/10.1371/journal.pone.0192640

Ejemplares similares

Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015
por: Wagenvoort, Gertjan H J, et al.
Publicado: (2017)

Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands
por: van Lier, Alies, et al.
Publicado: (2010)

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: Knol, Mirjam J., et al.
Publicado: (2015)

Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands
por: Rodenburg, Gerwin D., et al.
Publicado: (2010)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: van Deursen, Anna M.M., et al.
Publicado: (2012)

Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control
por: Thorrington, Dominic, et al.
Publicado: (2018)

Temporal cross‐correlation between influenza‐like illnesses and invasive pneumococcal disease in The Netherlands
por: Hendriks, Wilke, et al.
Publicado: (2017)

Increase in invasive disease caused by Haemophilus influenzae b, the Netherlands, 2020 to 2021
por: Steens, Anneke, et al.
Publicado: (2021)

Evaluation of the surveillance system for invasive meningococcal disease (IMD) in the Netherlands, 2004–2016
por: Brandwagt, Diederik A. H., et al.
Publicado: (2019)

Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018
por: Knol, Mirjam J, et al.
Publicado: (2018)

Disease Burden of 32 Infectious Diseases in the Netherlands, 2007-2011
por: van Lier, Alies, et al.
Publicado: (2016)

The Clinical Picture and Severity of Invasive Meningococcal Disease Serogroup W Compared With Other Serogroups in the Netherlands, 2015–2018
por: Loenenbach, Anna D, et al.
Publicado: (2020)

Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines
por: de Boer, Pieter T., et al.
Publicado: (2018)

Pathogen- and Type-Specific Changes in Invasive Bacterial Disease Epidemiology during the First Year of the COVID-19 Pandemic in The Netherlands
por: Steens, Anneke, et al.
Publicado: (2022)

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
por: Mangen, Marie-Josée J., et al.
Publicado: (2015)

Socioeconomic Status Is Associated With Antibody Levels Against Vaccine Preventable Diseases in the Netherlands
por: Hoes, Joske, et al.
Publicado: (2018)

Disease burden of varicella versus other vaccine-preventable diseases before introduction of vaccination into the national immunisation programme in the Netherlands
por: van Lier, Alies, et al.
Publicado: (2019)

The burden of varicella from a parent's perspective and its societal impact in The Netherlands: an Internet survey
por: Wolleswinkel-van den Bosch, Judith H, et al.
Publicado: (2011)

Dynamics and Determinants of Pneumococcal Antibodies Specific against 13 Vaccine Serotypes in the Pre-Vaccination Era
por: Prins-van Ginkel, Annemarijn C., et al.
Publicado: (2016)

Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data.
por: de Melker, H E, et al.
Publicado: (2000)

Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine.
por: de Melker, H E, et al.
Publicado: (1997)

The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years
por: McDonald, Scott A., et al.
Publicado: (2022)

Sex differences in COVID-19 mortality in the Netherlands
por: Niessen, Annabel, et al.
Publicado: (2022)

Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022
por: van Iersel, Senna C.J.L., et al.
Publicado: (2023)

Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020
por: Middeldorp, Marit, et al.
Publicado: (2021)

Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022
por: Hoeve, Christina E, et al.
Publicado: (2023)

Hospitalization due to varicella in the Netherlands
por: van Lier, Alies, et al.
Publicado: (2011)

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
por: Rozenbaum, Mark H, et al.
Publicado: (2011)

Economic Costs of Measles Outbreak in the Netherlands, 2013–2014
por: Suijkerbuijk, Anita W.M., et al.
Publicado: (2015)

Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
por: Ohm, Milou, et al.
Publicado: (2021)

An evidence synthesis approach to estimating the incidence of symptomatic pertussis infection in the Netherlands, 2005–2011
por: McDonald, Scott A., et al.
Publicado: (2015)

Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England
por: van Hoek, Albert Jan, et al.
Publicado: (2016)

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
por: Huiberts, Anne J, et al.
Publicado: (2023)

A scenario modelling analysis to anticipate the impact of COVID-19 vaccination in adolescents and children on disease outcomes in the Netherlands, summer 2021
por: Ainslie, Kylie E C, et al.
Publicado: (2022)

Review of the burden of eating disorders: mortality, disability, costs, quality of life, and family burden
por: van Hoeken, Daphne, et al.
Publicado: (2020)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
por: Thorrington, Dominic, et al.
Publicado: (2017)

1439. The Cost-Effectiveness of Vaccinating Adults at Increased Risk of Pneumococcal Disease Against Pneumococcal Disease in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021–January 2022
por: de Gier, Brechje, et al.
Publicado: (2023)

Measles Outbreak, the Netherlands, 2008
por: Hahné, Susan, et al.
Publicado: (2010)

The potential economic value of influenza vaccination for healthcare workers in The Netherlands
por: Meijboom, Marjan J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_34pa93ng0mr6s2oblkft4fatv7